ResearchMoz

LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 42

GlobalDatas pharmaceuticals report, LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020 provides LY2189265 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of LY2189265 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of LY2189265 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for LY2189265 in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 LY2189265 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase II 25
7.3.2 Phase III 25
7.4 Factors Affecting Sales of LY2189265 26
7.4.1 Once Weekly Dosage 26
7.4.2 Competition from Januvia 26
7.4.3 Approval of Bydureon 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 27
7.6.1 Target Patient Pool for LY2189265 27
7.6.2 Dosing 27
7.6.3 Market Penetration 28
7.6.4 Annual Cost of Therapy 29
7.6.5 Sales Projections of LY2189265 30

8 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 39
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Number of patients approved to take the drug 40
8.3.5 Net Penetration of Drug 41
8.3.6 Net Annual Dosing 41
8.3.7 Annual Cost of Therapy 41
8.4 Drug Sales Estimates Model 41
8.5 Contact Us 41
8.6 Disclaimer 41
8.7 Sources 42

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of LY2189265 26
Table 10: Estimated Annual Cost of Therapy of LY189265, 2014 29
Table 11: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Table 12: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Table 13: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Table 14: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Table 15: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Table 16: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20142020 35
Table 17: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Table 18: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
Figure 12: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Figure 13: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Figure 14: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Figure 15: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Figure 16: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Figure 17: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 35
Figure 18: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Figure 19: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37
Figure 20: LY2189265, Type 2 Diabetes, Global, Sales Distribution (%), 2020 38
Figure 21: Patients Approved for the Drug 40

Upcoming Reports:

Greece: market of pumpkins, squash and gourds
By - Williams and Marshal Strategy
ash and gourds market in Greece includes: Analysis and dynamics of the economy of Greece; Forecast for the development of the economy of Greece; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and analysis of imports; Volume, dynamics and analysis of exports; Volume, dynamics and analysis of consumption; Characteristics of the main market participants (manufacturers, importers and exporters);...
Poland: vegetable oils market
By - Williams and Marshal Strategy
g its development. Last but not least, the report presents a general overview of the economy of Poland in 2008-2012 and a forecast for its development in the medium term. The report on the vegetable oils market in Poland includes: Analysis and dynamics of the economy of Poland; Forecast for the development of the economy of Poland; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and analysis of...
Separation Systems For Commercial Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Separation of proteins and biomolecules such as DNA, RNA is an integral process during production of commercial biotechnology products. This requires use of variety of separating systems such as liquid chromatography, gas chromatography, microarray, membrane filtration, electrophoresis, magnetic separation and flow cytometry. The global market for the separation systems for commercial biotechnology market is growing rapidly owing to the increased demand for the biotechnological products, innovation and improvisation in the separation technology itself. The separation systems...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...